The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
A Cross-Sectional Study of Cannabidiol Users
Open accessAbstract
Introduction: Preclinical and clinical studies suggest that cannabidiol (CBD) found in Cannabis spp. has broad therapeutic value. CBD products can currently be purchased online, over the counter and at Cannabis-specific dispensaries throughout most of the country, despite the fact that CBD is generally deemed a Schedule I controlled substance by the U.S. Drug Enforcement Administration and renounced as a dietary supplement ingredient by the U.S. Food and Drug Administration. Consumer demand for CBD is high and growing, but few studies have examined the reasons for increasing CBD use. Materials and Methods: A self-selected convenience sample (n = 2409) was recruited via an online survey designed to characterize whom, how, and why individuals are currently using CBD. The anonymous questionnaire was accessed from October 25, 2017 to January 25, 2018. Participants were recruited through social media. Results: Almost 62% of CBD users reported using CBD to treat a medical condition. The top three medical conditions were pain, anxiety, and depression. Almost 36% of respondents reported that CBD treats their medical condition(s) “very well by itself,” while only 4.3% reported “not very well.” One out of every three users reported a nonserious adverse effect. The odds of using CBD to treat a medical condition were 1.44 (95% confidence interval, 1.16–1.79) times greater among nonregular users of Cannabis than among regular users. Conclusion: Consumers are using CBD as a specific therapy for multiple diverse medical conditions—particularly pain, anxiety, depression, and sleep disorders. These data provide a compelling rationale for further research to better understand the therapeutic potential of CBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin
Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I., Watkins, L. R., Wang, H., Abumrad, N., Eaton, J. W., & Tracey, K. J. (2000) · Nature · doi:10.1038/35013070 · Cited by 4,211
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Physiology and immunology of the cholinergic antiinflammatory pathway
Tracey, K. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30555 · Cited by 1,563
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Malfait, A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., & Feldmann, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.160105897 · Cited by 669
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Johnson, J. R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E. D., Potts, R., & Fallon, M. T. (2010) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2009.06.008 · Cited by 622
McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17030325 · Cited by 617
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535
Labeling Accuracy of Cannabidiol Extracts Sold Online
Bonn-Miller, M. O., Loflin, M. J. E., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017) · JAMA · doi:10.1001/jama.2017.11909 · Cited by 529
Mechoulam, R., & Shvo, Y. (1963) · Tetrahedron · doi:10.1016/0040-4020(63)85022-x · Cited by 486
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357
A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy
Sexton, M., Cuttler, C., Finnell, J. S., & Mischley, L. K. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0007 · Cited by 336
Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I
Adams, R., Hunt, M., & Clark, J. H. (1940) · Journal of the American Chemical Society · doi:10.1021/ja01858a058 · Cited by 298
Abuhasira, R., Shbiro, L., & Landschaft, Y. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.001 · Cited by 251
The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors
Bakas, T., van Nieuwenhuijzen, P. S., Devenish, S. O., McGregor, I. S., Arnold, J. C., & Chebib, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.022 · Cited by 246
Costa, B., Colleoni, M., Conti, S., Parolaro, D., Franke, C., Trovato, A. E., & Giagnoni, G. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-004-0871-3 · Cited by 242
Cannabinoids in treatment-resistant epilepsy: A review
O'Connell, B. K., Gloss, D., & Devinsky, O. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.11.012 · Cited by 226
Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice
Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., & Gallily, R. (2006) · Autoimmunity · doi:10.1080/08916930500356674 · Cited by 215
Adenosine and cAMP are potent inhibitors of the NF‐κB pathway downstream of immunoreceptors
Minguet, S., Huber, M., Rosenkranz, L., Schamel, W. W. A., Reth, M., & Brummer, T. (2005) · European Journal of Immunology · doi:10.1002/eji.200425524 · Cited by 197
Kozela, E., Lev, N., Kaushansky, N., Eilam, R., Rimmerman, N., Levy, R., Ben‐Nun, A., Juknat, A., & Vogel, Z. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01379.x · Cited by 190
Δ9 Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells
Srivastava, M. D., Srivastava, B. I. S., & Brouhard, B. (1998) · Immunopharmacology · doi:10.1016/s0162-3109(98)00041-1 · Cited by 189
Schier, A. R. D. M., Ribeiro, N. D. C. R., Coutinho, D. C. O., Machado, S. E. D. C., Arias-Carrión, Ó., Crippa, J. A. S., Zuardi, A. W., Nardi, A. E., & Silva, A. R. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612114838 · Cited by 177
Lee, J. L. C., Bertoglio, L. J., Guimarães, F. S., & Stevenson, C. W. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13724 · Cited by 158
In the weeds: a baseline view of cannabis use among legalizing states and their neighbours
Pacula, R. L., Jacobson, M., & Hernandez, E. J. M. (2015) · Addiction · doi:10.1111/add.13282 · Cited by 149
Cannabidiol arrests onset of autoimmune diabetes in NOD mice
Weiss, L., Zeira, M., Reich, S., Slavin, S., Raz, I., Mechoulam, R., & Gallily, R. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.029 · Cited by 147
Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation
BURSTEIN, S. H., & Zurier, R. B. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9084-5 · Cited by 139
Jadoon, K. A., Tan, G. D., & O’Sullivan, S. E. (2017) · JCI Insight · doi:10.1172/jci.insight.93760 · Cited by 136
Analgesic and antiinflammatory activity of constituents ofCannabis sativa L.
Formukong, E. A., EVANS, A. T., & Evans, F. J. (1988) · Inflammation · doi:10.1007/bf00915771 · Cited by 133
Fernandes, E. S., Liang, L., Smillie, S.-J., Kaiser, F., Purcell, R. H., Rivett, D. W., Alam, S., Howat, S., Collins, H., Thompson, S. J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102147 · Cited by 132
Influence of cannabidiol on delta‐9‐tetrahydrocannabinol effects
Dalton, W. S., Martz, R. C., Lemberger, L., Rodda, B. E., & Forney, R. B. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976193300 · Cited by 123
Watzl, B., Scuderi, P., & WATSON, R. R. (1991) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(91)90160-9 · Cited by 111
Effects of Δ 9 -Tetrahydrocannabinol and Cannabinol in Man
Karniol, I. G., Shirakawa, I., Takahashi, R. N., Knobel, E., & Musty, R. E. (2008) · Pharmacology · doi:10.1159/000136944 · Cited by 103
Serotonin upregulates the activity of phagocytosis through 5‐HT1A receptors
Freire‐Garabal, M., Núñez, M. J., Balboa, J. L., López‐Delgado, P., Gallego, R., García‐Caballero, T., Fernández‐Roel, M. D., Brenlla, J., & Rey‐Méndez, M. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705188 · Cited by 94
Production of superoxide and TNF-α from alveolar macrophages is blunted by glycine
Wheeler, M. D., & Thurman, R. G. (1999) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1999.277.5.l952 · Cited by 94
Keating, G. M. (2017) · Drugs · doi:10.1007/s40265-017-0720-6 · Cited by 92
Interactions in man of delta‐9‐tetrahydrocannabinol; II. Cannabinol and cannabidiol
Hollister, L. E., & Gillespie, H. K. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518180 · Cited by 86
Gururajan, A., TAYLOR, D. A. H. B., & Malone, D. T. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441865 · Cited by 83
Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke
Hayakawa, K., Mishima, K., & Fujiwara, M. (2010) · Pharmaceuticals · doi:10.3390/ph3072197 · Cited by 78
Wilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J., Cabrera, R., Maldonado, R. L., Cravatt, B. F., & Lichtman, A. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.015 · Cited by 78
Tetrahydrocannabinol inhibition of macrophage nitric oxide production
Coffey, R. G., Yamamoto, Y., Snella, E. M., & Pross, S. H. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00356-5 · Cited by 77
Petrat, F., Boengler, K., Schulz, R., & de GROOT, H. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01711.x · Cited by 68
Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders
Jurkus, R., Day, H. L. L., Guimarães, F. S., Lee, J. L. C., Bertoglio, L. J., & Stevenson, C. W. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00454 · Cited by 64
Trevethick, M. A., Mantell, S. J., Stuart, E. F., Barnard, A., Wright, K. N., & Yeadon, M. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.329 · Cited by 60
Sands, W. A., Martin, A. F., Strong, E. W., & Palmer, T. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.001107 · Cited by 58
Rovare, V. P. D. [., Magalhães, G. P. A., Jardini, G. D. A., Beraldo, M. L., Gameiro, M. O., Agarwal, A., Luvizutto, G. J., Ramos, L. D. P., Camargo, S. E. A., de Oliveira, L. D., et al. (2017) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2017.08.010 · Cited by 45
Cited by
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals
Legare, C. A., Raup-Konsavage, W. M., & Vrana, K. E. (2022) · Pharmacology · doi:10.1159/000521683 · Cited by 275
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00326-8 · Cited by 143
Baldino, L., Scognamiglio, M., & Reverchon, E. (2020) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2020.104960 · Cited by 129
Metadata
- Authors
- Corroon, J., & Phillips, J. A.
- Venue
- Cannabis and Cannabinoid Research
- Publisher
- SAGE Publications
- Published
- 2018-07
- Volume
- 3
- Issue
- 1
- Pages
- 152-161
- ISSN
- 2378-8763 (ISSN-L)
- OpenAlex
- W2868713882
- Cited by
- 289
- References
- 53
- FWCI
- 16.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.